DUBLIN, May 28, 2021 / PRNewswire / – Alkermes plc (Nasdaq: ALKS) announced today that it will host a webcast and conference call at 4:00 p.m. ET (9:00 p.m. BST) at Friday June 4, 2021 to review data updates presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting of the Company’s ARTISTRY-1 and ARTISTRY-2 clinical trials evaluating the nemvaleukin alfa (nemvaleukin) candidate for immuno- oncology. The company will provide an overview of the data presented, followed by a panel discussion with expert oncologists and researchers from the ARTISTRY clinical program, Valentina boni, MD, Ph.D., medical oncologist and principal investigator, START Madrid at the Centro Integral Oncológico Clara Campal; and Omid Hamid, MD, chief of research and immunotherapy, The Angeles Clinic and Research Institute.
Investor and analyst webcast with expert oncologists
Date and time: Friday, June 4, 2021 at 4 p.m. ET (9:00 p.m. BST)
Compose: +1 877-407-2988 for US callers and +1 201-389-0923 for international callers.
Investors and analysts can also view slides and listen to the live audio webcast of the presentation on the Investors section of the Alkermes website at www.alkermes.com. A replay of the webcast will be archived on the company’s website for 30 days after the presentation.
Nemvaleukin poster presentations at ASCO
Title: ARTISTRY-1: Nemvaleukin Alfa as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors
Presenter: Valentina boni, MD, Ph.D., medical oncologist and principal investigator, START Madrid at the Centro Integral Oncológico Clara Campal, Madrid, Spain
Date / time of presentation: The on-demand poster discussion session will take place on June 4, 2021 at 9:00 a.m.ET.
Title: Selection of the recommended phase 2 dose (RP2D) for subcutaneous nemvaleukin alfa: ARTISTRY-2
Presenter: Omid Hamid, MD, Head of Research and Immuno-Oncology, The Angeles Clinic and Research Institute
Date of presentation: The poster presentation will be available on request for participants from June 4, 2021.
About Nemvaleukin alfa (“nemvaleukin”)
Nemvaleukin is an innovative and experimental fusion protein composed of modified interleukin-2 (IL-2) and the high-affinity IL-2 alpha receptor chain, designed to selectively expand tumor-killing immune cells while simultaneously avoiding the activation of immunosuppressive cells by preferring binding to the IL-2 receptor complex of intermediate affinity. The selectivity of nemvaleukin is designed to take advantage of the proven anti-tumor effects of existing IL-2 therapy while alleviating some limitations.
About the ARTISTRY Clinical Development Program
ARTISTRY is an Alkermes sponsored clinical development program evaluating nemvaleukin alfa as a potential cancer immunotherapy. The ARTISTRY program includes multiple clinical trials evaluating intravenous and subcutaneous administration of nemvaleukin, both as monotherapy and in combination with anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors. Ongoing trials include: ARTIST-1, ARTIST-2, ARTIST-3 and ARTIST-6.
About Alkermes plc
Alkermes plc is a fully integrated global biopharmaceutical company developing innovative drugs in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, as well as a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
For investors: Sandy Coombs, +1 781 609 6377
For media: Sourojit Bhowmick, Ph.D. +1 781 609 6397
SOURCE Alkermes plc